JP2009544680A - ポリサッカライドによるタンパク質のｎ末端誘導体化 - Google Patents

ポリサッカライドによるタンパク質のｎ末端誘導体化 Download PDF

Info

Publication number
JP2009544680A
JP2009544680A JP2009521342A JP2009521342A JP2009544680A JP 2009544680 A JP2009544680 A JP 2009544680A JP 2009521342 A JP2009521342 A JP 2009521342A JP 2009521342 A JP2009521342 A JP 2009521342A JP 2009544680 A JP2009544680 A JP 2009544680A
Authority
JP
Japan
Prior art keywords
protein
sialic acid
polysaccharide
buffer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521342A
Other languages
English (en)
Japanese (ja)
Inventor
サンジャイ ジェイン
ピーター レイン
グレゴリー グレゴリアディス
Original Assignee
リポクセン テクノロジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リポクセン テクノロジーズ リミテッド filed Critical リポクセン テクノロジーズ リミテッド
Publication of JP2009544680A publication Critical patent/JP2009544680A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
JP2009521342A 2006-07-25 2007-07-25 ポリサッカライドによるタンパク質のｎ末端誘導体化 Pending JP2009544680A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117830 2006-07-25
PCT/GB2007/002839 WO2008012540A1 (en) 2006-07-25 2007-07-25 N-terminal polysialylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013022825A Division JP5420091B2 (ja) 2006-07-25 2013-02-08 ポリサッカライドによるタンパク質のｎ末端誘導体化

Publications (1)

Publication Number Publication Date
JP2009544680A true JP2009544680A (ja) 2009-12-17

Family

ID=37397314

Family Applications (14)

Application Number Title Priority Date Filing Date
JP2009521342A Pending JP2009544680A (ja) 2006-07-25 2007-07-25 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2009521343A Pending JP2009544681A (ja) 2006-07-25 2007-07-25 エリスロポエチンの多糖誘導体
JP2009521337A Expired - Fee Related JP5096466B2 (ja) 2006-07-25 2007-07-25 Ｎ末端ポリシアリル化
JP2009521336A Expired - Fee Related JP5419689B2 (ja) 2006-07-25 2007-07-25 顆粒球コロニー刺激因子の誘導体化
JP2012205475A Expired - Fee Related JP5586669B2 (ja) 2006-07-25 2012-09-19 Ｎ末端ポリシアリル化
JP2012287324A Expired - Fee Related JP5542195B2 (ja) 2006-07-25 2012-12-28 エリスロポエチンの多糖誘導体
JP2013022825A Expired - Fee Related JP5420091B2 (ja) 2006-07-25 2013-02-08 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2013160269A Expired - Fee Related JP5941440B2 (ja) 2006-07-25 2013-08-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2014025061A Expired - Fee Related JP6165079B2 (ja) 2006-07-25 2014-02-13 エリスロポエチンの多糖誘導体
JP2014154037A Expired - Fee Related JP5912152B2 (ja) 2006-07-25 2014-07-29 Ｎ末端ポリシアリル化
JP2015075148A Expired - Fee Related JP6055506B2 (ja) 2006-07-25 2015-04-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016020557A Expired - Fee Related JP6243456B2 (ja) 2006-07-25 2016-02-05 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016149090A Expired - Fee Related JP6203342B2 (ja) 2006-07-25 2016-07-29 エリスロポエチンの多糖誘導体
JP2017157728A Expired - Fee Related JP6581157B2 (ja) 2006-07-25 2017-08-18 エリスロポエチンの多糖誘導体

Family Applications After (13)

Application Number Title Priority Date Filing Date
JP2009521343A Pending JP2009544681A (ja) 2006-07-25 2007-07-25 エリスロポエチンの多糖誘導体
JP2009521337A Expired - Fee Related JP5096466B2 (ja) 2006-07-25 2007-07-25 Ｎ末端ポリシアリル化
JP2009521336A Expired - Fee Related JP5419689B2 (ja) 2006-07-25 2007-07-25 顆粒球コロニー刺激因子の誘導体化
JP2012205475A Expired - Fee Related JP5586669B2 (ja) 2006-07-25 2012-09-19 Ｎ末端ポリシアリル化
JP2012287324A Expired - Fee Related JP5542195B2 (ja) 2006-07-25 2012-12-28 エリスロポエチンの多糖誘導体
JP2013022825A Expired - Fee Related JP5420091B2 (ja) 2006-07-25 2013-02-08 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2013160269A Expired - Fee Related JP5941440B2 (ja) 2006-07-25 2013-08-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2014025061A Expired - Fee Related JP6165079B2 (ja) 2006-07-25 2014-02-13 エリスロポエチンの多糖誘導体
JP2014154037A Expired - Fee Related JP5912152B2 (ja) 2006-07-25 2014-07-29 Ｎ末端ポリシアリル化
JP2015075148A Expired - Fee Related JP6055506B2 (ja) 2006-07-25 2015-04-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016020557A Expired - Fee Related JP6243456B2 (ja) 2006-07-25 2016-02-05 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016149090A Expired - Fee Related JP6203342B2 (ja) 2006-07-25 2016-07-29 エリスロポエチンの多糖誘導体
JP2017157728A Expired - Fee Related JP6581157B2 (ja) 2006-07-25 2017-08-18 エリスロポエチンの多糖誘導体

Country Status (10)

Country Link
US (22) US8299015B2 (enExample)
EP (6) EP2043692B1 (enExample)
JP (14) JP2009544680A (enExample)
KR (1) KR101400105B1 (enExample)
CN (2) CN103169984B (enExample)
AT (1) ATE467642T1 (enExample)
DE (1) DE602007006492D1 (enExample)
ES (5) ES2344670T3 (enExample)
RU (1) RU2432175C2 (enExample)
WO (4) WO2008012540A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294535T3 (es) 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
CN103169984B (zh) * 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
US20110159130A1 (en) 2007-02-28 2011-06-30 Sanjay Jain Reduction of endotoxin in polysialic acids
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
RU2391354C1 (ru) * 2008-10-15 2010-06-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН, Российская Федерация, от имени которой выступает Федеральное агентство по науке и инновациям Комплекс биологически активного рекомбинантного белка с полисиаловой кислотой
MX2011004195A (es) * 2008-10-20 2011-09-27 Usv Ltd Un proceso mejorado para la pegilacion de proteinas.
CA2742064A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
JP2012516339A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 外因的刺激型制御放出物質体およびその使用
WO2010088294A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugate based systems for controlled drug delivery
RU2011135730A (ru) 2009-01-28 2013-03-10 Смартселлз, Инк. Кристаллические инсулин-коньюгаты
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) * 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CN101787117B (zh) * 2010-02-08 2012-05-23 江南大学 聚乙二醇-聚唾液酸嵌段共聚物的制备方法及应用
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
WO2011156242A2 (en) * 2010-06-11 2011-12-15 Lpath, Inc. Improved anti-lysophospholipid antibody design using antibody structures
WO2012015691A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
WO2012015681A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
EP2665814B1 (en) 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
US8962553B2 (en) 2011-11-17 2015-02-24 Cebix Ab Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
JP2019218265A (ja) * 2016-09-14 2019-12-26 生化学工業株式会社 ペプチドの血中滞留性を増強させる方法
WO2018197545A1 (en) * 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo
US20190083636A1 (en) * 2017-04-25 2019-03-21 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
US20220023430A1 (en) * 2018-11-13 2022-01-27 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
JP2022519586A (ja) * 2019-02-04 2022-03-24 ゼネティック バイオサイエンシーズ インコーポレイテッド 糖ポリシアル酸化治療用タンパク質を使用する方法
MX2022000285A (es) 2019-07-08 2022-02-03 Gi Innovation Inc Dimero de polipeptido con alto contenido de acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige y composicion farmaceutica que comprende el mismo.
CN116249552A (zh) * 2020-08-11 2023-06-09 隆延生物科技（上海）有限公司 一种液体制剂及其应用
CN114966021B (zh) * 2022-05-19 2025-03-04 山东博科生物产业有限公司 一种稳定的脂蛋白相关磷脂酶a2测定试剂盒

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733793A (ja) * 1993-07-23 1995-02-03 Snow Brand Milk Prod Co Ltd シアル酸粉末
JPH09506116A (ja) * 1994-10-12 1997-06-17 アムジエン・インコーポレーテツド Ｎ末端化学修飾タンパク質組成物および方法
JP2003533537A (ja) * 2000-05-16 2003-11-11 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化
WO2005016973A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Polysialic acid derivatives
WO2005016974A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
WO2006016168A2 (en) * 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
US5308617A (en) * 1988-08-10 1994-05-03 Halzyme Ltd. Protein heparin conjugates
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US7217689B1 (en) * 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
ES2115638T3 (es) 1991-12-30 1998-07-01 Akzo Nobel Nv Composicion tiroactiva de liberacion controlada.
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
WO1999043307A1 (en) 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
RU2141531C1 (ru) * 1999-05-26 1999-11-20 Российское акционерное общество открытого типа "Биопрепарат" Способ получения рекомбинантного инсулина человека
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
JP5178982B2 (ja) 2000-05-18 2013-04-10 セリックス， インコーポレイテッド 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2001290312A1 (en) * 2000-10-16 2002-04-29 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
AU3323002A (en) 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates
KR100401296B1 (ko) 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
WO2003055526A2 (en) 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
ITPD20010302A1 (it) 2001-12-28 2003-06-28 Bbs Riva Spa Dispositivo idraulico per pompare e / p intercettare metallo allo stato fuso
US6763226B1 (en) 2002-07-31 2004-07-13 Computer Science Central, Inc. Multifunctional world wide walkie talkie, a tri-frequency cellular-satellite wireless instant messenger computer and network for establishing global wireless volp quality of service (qos) communications, unified messaging, and video conferencing via the internet
MXPA05002594A (es) * 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
DE02020425T1 (de) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
US9040664B2 (en) * 2003-04-11 2015-05-26 Antriabio, Inc. Materials and methods for preparing protein-polymer conjugates
WO2004101619A1 (ja) 2003-05-15 2004-11-25 Shionogi Co., Ltd. 機能的糖ペプチドの合理的設計および合成
US7074755B2 (en) * 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
DE602004016170D1 (de) 2003-07-03 2008-10-09 Cipla Ltd Verfahren zur herstellung von finasterid form i
ATE345995T1 (de) 2003-08-05 2006-12-15 Dematic Corp Querantrieb für motorisierte rolle
AU2004263135B2 (en) * 2003-08-06 2010-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EP1660134B1 (en) 2003-08-08 2010-12-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and g-csf
NZ547168A (en) * 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
ES2422187T3 (es) * 2003-12-03 2013-09-09 Biogenerix Ag Factor estimulante de colonias de granulocitos glicopegilados
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP2336192A1 (en) * 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
FR2868071B1 (fr) * 2004-03-26 2006-06-09 Biomerieux Sa Reactifs de marquage, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
DE102004030392A1 (de) 2004-06-23 2006-01-19 Endress + Hauser Flowtec Ag, Reinach Meßwandler vom Vibrationstyp
WO2006014148A2 (fr) 2004-08-04 2006-02-09 Sergey Alexandrovich Orlov Procede permettant d'organiser un processus de jeu a action intermittente
GB2416993A (en) 2004-08-11 2006-02-15 Dinesh Verma Opthalmic prosthesis
EP1789454B1 (en) 2004-08-12 2017-07-05 Lipoxen Technologies Limited Fractionation of charged polysaccharide
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US8217154B2 (en) 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
WO2007047997A2 (en) * 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
CN103169984B (zh) * 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
JP2011037843A (ja) 2009-07-16 2011-02-24 Kao Corp 食後血中インスリン濃度上昇抑制剤
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733793A (ja) * 1993-07-23 1995-02-03 Snow Brand Milk Prod Co Ltd シアル酸粉末
JPH09506116A (ja) * 1994-10-12 1997-06-17 アムジエン・インコーポレーテツド Ｎ末端化学修飾タンパク質組成物および方法
JP2003533537A (ja) * 2000-05-16 2003-11-11 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化
WO2005016973A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Polysialic acid derivatives
WO2005016974A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
JP2007501889A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のためのシアル酸誘導体
WO2006016168A2 (en) * 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6011051325; Ｂｉｏｃｈｉｍ．　Ｂｉｏｐｈｙｓ．　Ａｃｔａ． ｖｏｌ．１６２２, 2003, ｐ．４２-９ *
JPN6011051329; Ｉｎｔ．　Ｊ．　Ｐｈａｒｍ． ｖｏｌ．３００, 2005, ｐ．１２５-３０ *

Also Published As

Publication number Publication date
US20140315802A1 (en) 2014-10-23
US8946406B2 (en) 2015-02-03
JP2015007062A (ja) 2015-01-15
US20150252090A1 (en) 2015-09-10
JP6581157B2 (ja) 2019-09-25
CN103169984B (zh) 2016-08-03
RU2432175C2 (ru) 2011-10-27
US20170119893A1 (en) 2017-05-04
JP2013100309A (ja) 2013-05-23
CN103169984A (zh) 2013-06-26
EP2043692B1 (en) 2016-05-18
WO2008012542A3 (en) 2008-05-15
ES2581902T3 (es) 2016-09-08
US9234020B2 (en) 2016-01-12
US8299026B2 (en) 2012-10-30
JP2013241446A (ja) 2013-12-05
US20180289823A1 (en) 2018-10-11
US9549990B2 (en) 2017-01-24
JP2009544681A (ja) 2009-12-17
RU2009105696A (ru) 2010-08-27
JP2018039791A (ja) 2018-03-15
JP2017018107A (ja) 2017-01-26
US20170058273A1 (en) 2017-03-02
US20100022441A1 (en) 2010-01-28
WO2008012542A8 (en) 2009-07-16
WO2008012525A8 (en) 2010-04-29
US20160129124A1 (en) 2016-05-12
US20150147307A1 (en) 2015-05-28
JP6055506B2 (ja) 2016-12-27
WO2008012525A1 (en) 2008-01-31
US20130116176A1 (en) 2013-05-09
KR20090057370A (ko) 2009-06-05
EP2043693B1 (en) 2016-04-27
JP5912152B2 (ja) 2016-04-27
CN101511391B (zh) 2013-03-13
US8299015B2 (en) 2012-10-30
ATE467642T1 (de) 2010-05-15
US20220133898A1 (en) 2022-05-05
EP2043616B1 (en) 2016-01-27
US20100056427A1 (en) 2010-03-04
ES2344670T3 (es) 2010-09-02
US8796207B2 (en) 2014-08-05
JP5542195B2 (ja) 2014-07-09
US9266936B2 (en) 2016-02-23
JP5586669B2 (ja) 2014-09-10
US8981050B2 (en) 2015-03-17
US20100022443A1 (en) 2010-01-28
US20150158924A1 (en) 2015-06-11
US8933026B2 (en) 2015-01-13
CN101511391A (zh) 2009-08-19
JP5096466B2 (ja) 2012-12-12
JP2016128493A (ja) 2016-07-14
JP2015145400A (ja) 2015-08-13
JP2013049675A (ja) 2013-03-14
JP2009544678A (ja) 2009-12-17
US9474805B2 (en) 2016-10-25
JP5419689B2 (ja) 2014-02-19
US9492557B2 (en) 2016-11-15
EP2043692A2 (en) 2009-04-08
JP2009544677A (ja) 2009-12-17
US20170080054A1 (en) 2017-03-23
ES2569066T3 (es) 2016-05-06
US20140134147A1 (en) 2014-05-15
JP6243456B2 (ja) 2017-12-06
DE602007006492D1 (de) 2010-06-24
ES2581983T3 (es) 2016-09-08
JP2014114315A (ja) 2014-06-26
EP2043616A1 (en) 2009-04-08
JP5420091B2 (ja) 2014-02-19
JP6203342B2 (ja) 2017-09-27
EP3299033A1 (en) 2018-03-28
WO2008012540A9 (en) 2009-03-12
EP2630972B1 (en) 2017-08-30
KR101400105B1 (ko) 2014-06-19
US20100016217A1 (en) 2010-01-21
JP5941440B2 (ja) 2016-06-29
US20160129123A1 (en) 2016-05-12
US20160095930A1 (en) 2016-04-07
US9492556B2 (en) 2016-11-15
US20140161765A1 (en) 2014-06-12
US20190216938A1 (en) 2019-07-18
US8394921B2 (en) 2013-03-12
EP2041167B1 (en) 2010-05-12
EP2041167A1 (en) 2009-04-01
US20140309166A1 (en) 2014-10-16
EP2043693A1 (en) 2009-04-08
JP2013121982A (ja) 2013-06-20
WO2008012528A1 (en) 2008-01-31
US9789163B2 (en) 2017-10-17
US10300144B2 (en) 2019-05-28
EP2630972A3 (en) 2013-10-16
EP2630972A2 (en) 2013-08-28
WO2008012542A2 (en) 2008-01-31
ES2647528T3 (es) 2017-12-22
US9579393B2 (en) 2017-02-28
US20140309407A1 (en) 2014-10-16
WO2008012540A1 (en) 2008-01-31
JP6165079B2 (ja) 2017-07-19
US9040478B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
JP6243456B2 (ja) ポリサッカライドによるタンパク質のｎ末端誘導体化
Class et al. Patent application title: N-Terminal Derivatisation of Proteins With Polysaccharides Inventors: Sanjay Jain (London, GB) Peter Laing (London, GB) Gregory Gregoriadis (London, GB) Assignees: Lipoxen Technologies Limited
Class et al. Patent application title: N-terminal Derivatisation of Proteins with Polysaccharides
Class et al. Patent application title: Derivatisation of Erythropoietin (EPO) Inventors: Sanjay Jain (London, GB) Peter Laing (London, GB) Gregory Gregoriadis (London, GB) Norbert Oskar Rumpf (London, GB) Norbert Oskar Rumpf (London, GB) Assignees: Lipoxen Technologies Limited
Class et al. Patent application title: DERIVATISATION OF GRANULOCYTE COLONY-STIMULATING FACTOR Inventors: Sanjay Jain (London, GB) Peter Laing (London, GB) Gregory Gregoriadis (London, GB) Assignees: Lipoxen Technologies Limited

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130528